Full Press Release Details
Channel Therapeutics Provides Announcement
on 2024 Annual Report to Comply with NYSE American Listing Rules
FREEHOLD, N.J., May 1, 2025 (GLOBE NEWSWIRE)
- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer
in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report
on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited
financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern
emphasis of matter paragraph.
information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent
any change or amendment to the Company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended
Channel Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to
alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for
the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates
Channel Media and Investor Inquires:
For Investor Inquiries:
Managing Director, LifeSci Advisors, LLC